Overview

“Cellular Classification,” Ovarian Epithelial Cancer Treatment (PDQ®)(Health Professional Version), National Cancer Institute, March 5, 2008.

“Cellular Classification,” Ovarian Germ Cell Tumors Treatment (PDQ®)(Health Professional Version), National Cancer Institute, December 21, 2007.

“General Information,” Ovarian Low Malignant Potential Tumors Treatment (PDQ®)(Health Professional Version), National Cancer Institute, December 21, 2007.

“What is Ovarian Cancer?” Detailed Guide: Ovarian Cancer, American Cancer Society, January 19, 2008.

“Types of Tumors,” Johns Hopkins Medical Institute, October 18, 2001.

“Primary and Secondary Ovarian Cancer,” Information-About-Ovarian-Cancer.com, March 4, 2008.

“Ovarian Cancer Types,” OncologyChannel, July, 11, 2007.

“Origin of Ovarian Cancer,” www.gyncancer.com.

Epithelial Ovarian Cancer

Clear Cell Carcinoma

Köbel M, Xu H, Bourne PA, Spaulding BO, Shih IM; Mao TL et. al. IGF2BP3 (IMP3) Expression Is a Marker of Unfavorable Prognosis in Ovarian Carcinoma of Clear Cell Subtype. Modern Pathology. 2009;22(3):469-475. [Epub 2009 Jan 9].

Glypican-3 expression in clear cell adenocarcinoma of the ovary. Maeda D, Ota S, Takazawa Y et. al. Mod Pathol. 2009 Mar 27. [Epub ahead of print]

Treatments of epithelial ovarian cancer by histologic subtype; Sugiyama T. et. al., Gan To Kagaku Ryoho. 2009 Feb;36(2):187-92 (“Recent molecular studies support the hypothesis that clear cell carcinoma and mucinous adenocarcinoma are refractory cancers that are biologically distinct from serous adenocarcinoma. Treatment of these cancers has not yet been adequately tested, so separate clinical trials are needed for each type. Paclitaxel …combined with carboplatin …is the current gold standard for treating ovarian cancer. Clear cell carcinoma and mucinous adenocarcinoma are less sensitive to a TC regimen than serous adenocarcinoma, and an international randomized trial for clear cell carcinoma is now underway(GCIG/JGOG3017). Targeted therapy is attractive for chemoresistant clear cell carcinoma, thus VEGFR inhibitor(sunitinib), PDGFR inhibitor(sorafenib), m-TOR inhibitor (temsirolimus), and monoclonal antibody(bevacizumab)are being evaluated.”)

Overexpression of Class III {beta}-Tubulin Predicts Good Response to Taxane-Based Chemotherapy in Ovarian Clear Cell Adenocarcinoma, Aoki D, Oda Y, Hattori S, Taguchi KI, Ohishi Y, Basaki Y et. al.; Clin Cancer Res. 2009 Feb 15;15(4):1473-1480 (In a small experimental design study, taxane-based chemotherapy was effective for patients with ovarian clear cell adenocarcinomas who were positive for beta-tubulin III but not for those who were negative for these proteins).

Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma; Miyazawa M, Yasuda M, Fujita M et. al., Pathol Int. 2009 Jan;59(1):19-27.

Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers; Chan JK et. al., Gynecol Oncol. 2008 Jun;109(3):370-6. Epub 2008 Apr 18.

Overexpression of osteopontin in clear cell carcinoma of the ovary: close association with HNF-1beta expression; Kato N, Motoyama T, Histopathology. 2008 May;52(6):682-8. Epub 2008 Apr 2.

Survival analysis of ovarian clear cell carcinoma confined to the ovary with or without comprehensive surgical staging; Takano M et. al., Oncol Rep. 2008 May;19(5):1259-64.

Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma; Itamochi H et. al, Can Sci 2008 Apr;99(4):653-658.

Hypomethylation of hepatocyte nuclear factor-1beta (HNF-1beta) CpG island in clear cell carcinoma of the ovary; Kato N, Tamura G, Motoyama T, Virchows Arch. 2008 Feb;452(2):175-80. Epub 2007 Dec 8.

An Up-to-Date Anti-Cancer Treatment Strategy Focusing on HIF-1α Suppression: Its Application for Refractory Ovarian Cancer; Fujita M et. al, Acta Histochem Cytochem. 2007 Dec 18;40(5):139-42.

Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma; Rauh-Hain JA, Penson RT, Int J Gynecol Cancer. 2007 Dec 13.

Prognostic analysis of 88 patients with ovarian clear cell carcinoma; Ma SK, Zhang HT, Wu LY, Liu LY, Zhonghua Zhong Liu Za Zhi. 2007 Oct;29(10):784-8.

Galectin-3 may contribute to Cisplatin resistance in clear cell carcinoma of the ovary; Oishi T et. al., Int J Gynecol Cancer. 2007 Sep-Oct;17(5):1040-6. Epub 2007 Apr 12.

Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis; Takano M et. al., Int J Clin Oncol. 2007 Aug;12(4):256-60. Epub 2007 Aug 20.

Irinotecan hydrochloride (CPT-11) and cisplatin as first-line chemotherapy after initial surgery for ovarian clear cell adenocarcinoma; Takakura S et. al., Int Surg. 2007 Jul-Aug;92(4):202-8.

Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma; Lee S, Garner EI, Welch WR, Berkowitz RS, Mok SC, Gynecol Oncol. 2007 Aug;106(2):311-7. Epub 2007 May 25.

RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model, Mabuchi S et. al., Clinical Cancer Research 2007 Jul; 13, 4261-4270.

HER2 overexpression and amplification in advanced ovarian cancer (AOC): Treatment with trastuzumab-A GINECO study, Guastalla JP, J. Clin Oncol 2007 (June Suppl); 25(18S): 5559.

Clear Cell Tumors of the Ovary – Rare Subtype of Ovarian Cancer, Sugiyama T., American Society of Clinical Oncology Educational Session, 2007 Annual Meeting, June 2, 2007.

RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer; Mabuchi S et. al., Cancer Res. 2007 Mar 15;67(6):2408-13.

Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary; Crotzer DR, Gynecol Oncol. 2007 May;105(2):404-8. Epub 2007 Feb 9.

Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer; Coronado Martín PJ et. al., Med Clin (Barc). 2007 Jan 13;128(1):1-6.

Ovarian clear cell adenocarcinoma: a continuing enigma; Tan DS et. al., J Clin Pathol. 2007 Apr;60(4):355-60. Epub 2006 Oct 3.

Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy; Itamochi H et. al., Mol Cancer Ther. 2007 Jan;6(1):227-35. Epub 2007 Jan 11.

Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary; Takano M et. al., Oncol Rep. 2006 Dec;16(6):1301-6.

Treatment Issues in Clear Cell Carcinoma of the Ovary: A Different Entity?, Pectasides D, The Oncologist, Vol. 11, No. 10, 1089-1094, November 2006; doi:10.1634/theoncologist.11-10-1089.

Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience; Pectasides D et. al, Gynecol Oncol. 2006 Aug;102(2):285-91. Epub 2006 Mar 3.

Proliferative activity of early ovarian clear cell adenocarcinoma depends on association with endometriosis; Komiyama S, Aoki D, Katsuki Y, Nozawa S., Eur J Obstet Gynecol Reprod Biol. 2006 Jul;127(1):130-6. Epub 2006 Jan 27.

Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging; Takano M, Br J Cancer. 2006 May 22;94(10):1369-74.

PTEN expression in clear cell adenocarcinoma of the ovary; Hashiguchi Y, Tsuda H, Inoue T, Berkowitz RS, Mok SC, Gynecol Oncol. 2006 Apr;101(1):71-5. Epub 2005 Nov 10.

Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary; Kato N, Sasou S, Motoyama T, Mod Pathol. 2006 Jan;19(1):83-9.

Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer; Zorn KK, et. al., Clin Cancer Res. 2005 Sep 15;11(18):6422-30.

Complete response to irinotecan hydrochloride and nedaplatin in a patient with advanced ovarian clear cell carcinoma; Nishida M, International Journal of Clin Onc 2004 Oct.; 9(5): 403-405.

Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma; Tanabe H et. al., Gynecol Oncol. 2004 Sept; 94(3): 735-739.

Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease; Ho CM et. al., Gynecol Oncol. 2004 Jul;94(1):197-203.

Gene Expression Patterns in Ovarian Carcinomas; Schaner ME et. al., Mol. Bio. Cell 2003 Dec.; 14(11):4376-4386.

HER-2/neu expression in ovarian clear cell carcinomas; Iwamoto H, International J. Gynec Oncol 2003 Mar; 13(1): 28-31.

Evaluation of Monoclonal Humanized Anti-HER2 Antibody, Trastuzumab, in Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma With Overexpression of HER2: A Phase II Trial of the Gynecologic Oncology Group; Bookman MA et. al., J Clin Oncol, 2003 Jan; 21(2): 283-290

Phase II Trial of Irinotecan in Patients With Metastatic Epithelial Ovarian Cancer or Peritoneal Cancer; Bodurka DC, Journal of Clin Onc 2003 Jan; 21(2): 291-297.

HER2 Is Frequently Over-expressed in Ovarian Clear Cell Adenocarcinoma: Possible Novel Treatment Modality Using Recombinant Monoclonal Antibody against HER2, Trastuzumab; Fujimura M, Jpn. J. Cancer Res 2002 Nov.; 93: 1250-1257.

Gene Expression in Ovarian Cancer Reflects Both Morphology and Biological Behavior, Distinguishing Clear Cell from Other Poor-Prognosis Ovarian Carcinomas; Schwartz DR, Cancer Research 2002 Aug; 62, 4722-4729

Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary; Itamochi H, Obstet Gynecol. 2002 Aug;100(2):281-7.

Clear cell carcinoma of the ovary: a remarkable case; Giblin J, Fanucchi MP, McGuire WP, Am J Clin Oncol. 2001 Feb;24(1):99-100.

Camptothecin and mitomycin combination chemotherapy on ovarian clear cell carcinoma with multiple systemic metastases; Tanaka T, Umesaki N, Ogita S, Eur J Gynaecol Oncol. 2000;21(4):377-9.

A Pilot Study of CPT-11 and Cisplatin for Ovarian Clear Cell Adenocarcinoma; Adachi S et. al., Japanese Journal of Clin Oncol; 1999 June; 29(9): 434-437.

HER-2/neu amplification and overexpression in endometrial carcinoma; Rolitsky CD et. al., Int J Gynecol Pathol. 1999 Apr;18(2):138-43.

Chemotherapy for ovarian clear cell adenocarcinoma with irinotecan hydrochloride and mitomycin C; Umezawa S et. al., International Journal of Clin Onc 1996 Sept; 1(3): 157-162.

Germ Cell Ovarian Cancer

Sex Cord Stromal Ovarian Cancer

Angiogenesis Linked to Poor Survival in Patients With Rare Type of Ovarian Cancer – Drugs that block new blood vessel formation may improve outcomes of patients with sex cord-stromal tumors, M.D. Anderson Cancer Center News Release, Feb. 5, 2009 (Researchers from The University of Texas M. D. Anderson Cancer Center found that increased angiogenesis, or blood vessel formation, and vascular endothelial growth factor expression are associated with poor survival in women with sex cord-stromal ovarian tumors. This data was presented in a poster session).

Rare Forms of Ovarian Cancer

Fibrosarcoma

Small Cell Carcinoma